Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.
|Number of pages||5|
|Journal||International Journal of Biochemistry and Cell Biology|
|Early online date||23 Dec 2017|
|Publication status||Published - Feb 2018|
Bibliographical note© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
Bennett, J., Capece, D., Begalli, F., Verzella, D., D'Andrea, D., Tornatore, L., & Franzoso, G. (2018). NF-κB in the crosshairs: Rethinking an old riddle. International Journal of Biochemistry and Cell Biology, 95, 108-112. https://doi.org/10.1016/j.biocel.2017.12.020